Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
Novo Nordisk makes the app available for free
InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of cobitolimod for the treatment of inflammatory diseases.
InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose optimisation study with the drug candidate cobitolimod.
Novo Nordisk today announced that the US Food and Drug Administration has published the briefing documents ahead of the Advisory Committee meeting to discuss the supplemental New Drug Application for approval of Victoza injection.